Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

7,331 total articles

Director Bobbili Raja Acquires $12.3 Million in ContextLogic Shares

Director Bobbili Raja Acquires $12.3 Million in ContextLogic Shares

On February 26, 2026, director Bobbili Raja purchased 1,758,794 shares of ContextLogic Holdings Inc. (NASDAQ: LOGC) at $7.00 per share, a transaction valued at $12,311,558. Following the purchase, Raja's indirect holdings across several investment vehicles total 18,269,534 shares. The stock is trading at $7.98 with a market capitalization of $215 m…

BioMarin Legal Executive Disposes $1.6M in Stock; Company Posts Mixed Q4 Results and Sees Analyst Target Moves

BioMarin Legal Executive Disposes $1.6M in Stock; Company Posts Mixed Q4 Results and Sees Analyst Target Moves

George Eric Davis, BioMarin Pharmaceutical's Executive Vice President and Chief Legal Officer, sold 26,061 shares of company stock on February 26, 2026, for about $1.6 million. The transaction occurred near the stock's trading level, while the company reported fourth-quarter 2025 results that beat revenue expectations but missed on EPS. Multiple an…

PennyMac Legal Chief Sells $174,124 in Automatic Plan Trade

PennyMac Legal Chief Sells $174,124 in Automatic Plan Trade

PennyMac Financial Services Chief Legal Officer Derek Stark sold 1,903 shares under a Rule 10b5-1 plan on February 25, 2026, generating about $174,124. The transactions follow tax-withholding of 345 shares tied to vested restricted stock units and come amid a sharp year-to-date share decline and a notable Q4 2025 earnings miss for the firm.

ReposiTrak CEO's Pre-Set Plan Yields $62,891 in Stock Sales

ReposiTrak CEO's Pre-Set Plan Yields $62,891 in Stock Sales

ReposiTrak Chief Executive Officer Randall K. Fields sold 7,500 shares of common stock across February 24 and 25, 2026, through a pre-arranged Rule 10b5-1 plan, generating $62,891 in proceeds. The transactions were reported on a Form 4 filing with the SEC. The company has also declared a quarterly dividend, authorized a new 10b5-1 buyback allocatio…

BlackRock Senior Managing Director Disposes $2.58M in Company Shares

BlackRock Senior Managing Director Disposes $2.58M in Company Shares

BlackRock Senior Managing Director J. Richard Kushel sold 2,385 shares of BlackRock stock on February 24, 2026, in two transactions that generated $2.58 million in proceeds. The trades were executed at prices between $1,083.05 and $1,084.9101 per share. After the sales, Kushel retains both direct and indirect holdings in the company. The transactio…

Vertex EVP Sells $126K in Stock as Company Nears 52-Week High

Vertex EVP Sells $126K in Stock as Company Nears 52-Week High

Ourania Tatsis, Executive Vice President at Vertex Pharmaceuticals, sold shares under a pre-established Rule 10b5-1 trading plan, disposing of 1,887 shares across two days for roughly $915,724. The trades were filed on a Form 4 with the SEC. Vertex shares trade near their 52-week high even as the company reported a slight EPS miss for Q4 2025 and a…

Vertex Executive Sells Nearly $1.6M in Stock Across Two Days

Vertex Executive Sells Nearly $1.6M in Stock Across Two Days

Amit Sachdev, Vertex Pharmaceuticals' Executive Vice President and Chief Patient & External Affairs Officer, executed two share dispositions across February 24-25, 2026, via a company-approved 10b5-1 trading plan. The transactions reduced his directly held stake while leaving him with substantial direct and indirect holdings. The stock sales oc…

Vertex Executive Sells $2.39M in Stock as Company Nears 52-Week High

Vertex Executive Sells $2.39M in Stock as Company Nears 52-Week High

Duncan McKechnie, Vertex Pharmaceuticals' Executive Vice President and Chief Commercial Officer, sold a total of 5,783 shares across February 24-25, 2026, generating roughly $2.81 million in proceeds. The transactions were executed under a 10b5-1 plan and reported via a Form 4 filing. The trade comes while Vertex shares trade near their 52-week hig…